Demographic baseline characteristics of patients
| Solid epithelial tumorsa | Metastatic colorectal cancer | ||
|---|---|---|---|
| Dose escalation | 12 mg/kg | 9 mg/kg | |
| Full analysis set | 20 (100) | 29 (100) | 13 (100) |
| Age (years) | |||
| Median | 61 | 63 | 68 |
| Min–max | 35–81 | 35–84 | 52–79 |
| Sex (N, %) | |||
| Female | 13 (65) | 14 (48) | 6 (46) |
| Male | 7 (35) | 15 (52) | 7 (54) |
| Previous treatment for mCRC (N, %) | |||
| Bevacizumab | NA | 18 (62) | 5 (39) |
| Irinotecan | NA | 25 (86) | 12 (92) |
| Oxaliplatin | NA | 24 (83) | 10 (77) |
| Previous anti-EGFR treatment | |||
| Any | NA | 29 (100) | 13 (100) |
| Any cetuximab treatment | NA | 22 (76) | 11 (85) |
| Any panitumumab treatment | NA | 13 (45) | 3 (23) |
| More than one line of mAb treatment | NA | 13 (45) | 1 (8) |
| Previous treatment lines (N, %)b | |||
| 1–3 | NA | 15 (52) | 9 (69) |
| >3 | NA | 14 (48) | 4 (31) |
| Metastatic sitesc | |||
| Liver | NA | 23 (79) | 8 (62) |
| Lung | NA | 12 (41) | 7 (54) |
| Lymph nodes | NA | 6 (21) | 5 (39) |
| Other | NA | 4 (14) | 2 (15) |
Abbreviations: NA, not assessed; mCRC, metastatic colorectal cancer.
↵aOf 20 patients with solid epithelial tumors, 14 had colorectal cancer, 3 pancreatic cancer, 2 non–small cell lung cancer, and 1 spinal chordoma.
↵bIncluding antitumor compounds aflibercept, sorafenib, ramucirumab, carlumab, deforolimus, ganitumab, trebananib, and cediranib.
↵cMultiple nominations of metastatic sites identified as target lesions per patient possible.